Literature DB >> 1968075

Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells.

T Herrmann1, J L Maryanski, P Romero, B Fleischer, H R MacDonald.   

Abstract

The T cell response to microbial T cell mitogens (MTM) such as enterotoxins from Staphylococcus aureus (SE) and the soluble mitogen from Mycoplasma arthritidis, resemble the minor lymphocyte stimulatory locus (Mls) response in several aspects. An important feature of the Mls response is it restriction to CD4+ cells. This study demonstrates that in contrast to Mls, the MTM response includes both CD4+ and CD8+ subsets. Both CD4+ and CD8+ cells expanded in IL-2 after stimulation with SEB showed preferential expression of T cell receptors bearing V beta 8 domains. Mouse and human target cells could be lysed in the presence of MTM both by MTM-stimulated CD8+ lymphocytes and by MHC class I-restricted CTL clones of defined Ag specificity. MTM-induced lysis required the expression of MHC class II, but not class I Ag, on the target cells. Inhibition studies of SEB and Ag-dependent cytolysis by CTL clones underlined the crucial role of CD3 and LFA-1 in both instances, but showed CD8 dependence only for AG-dependent cytolysis. Together these findings suggest important differences between the putative MTM-mediated interaction of TCR with MHC molecules and the classical TCR/MHC interaction involved in MHC-restricted Ag recognition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968075

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Enterotoxins can support CAR T cells against solid tumors.

Authors:  Bianca von Scheidt; Minyu Wang; Amanda J Oliver; Jack D Chan; Metta K Jana; Aesha I Ali; Fiona Clow; John D Fraser; Kylie M Quinn; Phillip K Darcy; Michael H Kershaw; Clare Y Slaney
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-25       Impact factor: 11.205

2.  The stage of negative selection in tolerance induction in neonatal mice.

Authors:  T Ando; Y Yoshikai; G Matsuzaki; H Takimoto; K Nomoto
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

3.  Direct binding of secreted T-cell receptor beta chain to superantigen associated with class II major histocompatibility complex protein.

Authors:  N R Gascoigne; K T Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

4.  Differential regulation of cytokine production by CD1d-restricted NKT cells in response to superantigen staphylococcal enterotoxin B exposure.

Authors:  Melanie J Ragin; Nisebita Sahu; Avery August
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  Staphylococcal enterotoxin A and toxic shock syndrome toxin compete with CD4 for human major histocompatibility complex class II binding.

Authors:  S Bavari; R G Ulrich
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

Review 6.  Microbial "superantigens".

Authors:  M L Misfeldt
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

Review 7.  Bacterial and viral superantigens: roles in autoimmunity?

Authors:  H Acha-Orbea
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

8.  Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.

Authors:  M Dohlsten; G Hedlund; E Akerblom; P A Lando; T Kalland
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

Review 9.  Monoclonal antibodies and superantigens: a novel therapeutic approach.

Authors:  T Kalland; M Dohlsten; P Lind; A Sundstedt; L Abrahmsén; G Hedlund; P Björk; P A Lando; M Björklund
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

10.  In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor.

Authors:  K A Newell; J D Ellenhorn; D S Bruce; J A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.